Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed challenges affecting the company's performance [3][4]. Group 1: Allegations Against RxSight - The complaint alleges that RxSight and its executives made false or misleading statements regarding the company's sales and utilization, overstated product demand, and failed to meet previously issued financial guidance for fiscal year 2025 [3]. - Specific issues cited include "adoption challenges" and structural problems leading to declines in sales and utilization, which were not disclosed to investors [3]. Group 2: Financial Impact - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, along with a lowered full-year guidance by approximately $42.5 million at the midpoint [4]. - Following this announcement, RxSight's stock price dropped by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, amid unusually high trading volume [4]. Group 3: Legal Proceedings - Investors who suffered losses in RxSight are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of September 22, 2025, to seek the role of lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Flywire Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline on September 23, 2025 [1]. Group 1: Class Action Details - Investors who purchased Flywire securities between February 28, 2024, and February 25, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [3]. - The lawsuit claims that Flywire's management made false and misleading statements regarding the company's revenue growth and the impact of permit and visa-related restrictions on its business [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Replimune securities class action is from November 22, 2024, to July 21, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial's prospects, which were known to be inadequate by the defendants [5]. - The U.S. Food and Drug Administration (FDA) deemed the IGNYTE trial inadequate and not well-controlled, impacting the credibility of Replimune's business statements [5]. - Investors suffered damages when the true details about the trial and the company's operations were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in recovering funds for clients [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Quantum Corporation due to allegations of false and misleading statements regarding its financial reporting and revenue recognition [2][3]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $75,000 in Quantum Corporation between November 15, 2024, and August 18, 2025, to discuss their legal options [1][2]. - A federal securities class action has been filed against Quantum Corporation, with a deadline of November 3, 2025, for investors to seek the role of lead plaintiff [2][8]. Group 2: Allegations Against Quantum Corporation - The lawsuit claims that Quantum Corporation improperly recognized revenue for the fiscal year ended March 31, 2025, necessitating a restatement of its financial statements for the fiscal third quarter ended December 31, 2024 [3]. - Quantum Corporation disclosed on June 30, 2025, that it would be unable to timely file its annual financial report due to a review of its accounting related to certain revenue contracts, leading to a stock price drop of $1.00, or 10.03%, closing at $8.97 per share [4]. - On August 8, 2025, Quantum announced that its third quarter 2024 financial statements should no longer be relied upon due to deficiencies in internal controls, resulting in a revenue decrease of approximately $3.9 million [5]. - Following the announcement of its CEO's resignation on August 18, 2025, Quantum's stock price fell by $0.61, or 8.2%, closing at $6.83 per share [7].

LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Alto Neuroscience, Inc. ("Alto " or "the Company") (NYSE: ANRO ) for violations of the federal securities laws.Shareholders who purchased shares of Alto during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD:  pursuant and/or traceable to Alto's initia ...

Group 1 - The lawsuit against C3.ai, Inc. involves allegations of failing to disclose material information during the Class Period, violating federal securities laws [3] - The Class Period for the lawsuit is defined as from February 26, 2025, to August 8, 2025, and investors have until October 21, 2025, to file lead plaintiff applications [1][3] - Following the disclosure of disappointing preliminary financial results for Q1 2026 and a reduction in revenue guidance, C3's share price dropped approximately 25.58%, from $22.13 on August 8, 2025, to $16.47 on August 11, 2025 [4] Group 2 - The lawsuit is identified as John Liggett Sr. v. C3.ai, Inc., et al., No. 25-cv-07129, and is pending in the United States District Court for the Northern District of California [4] - ClaimsFiler provides a free service to help retail investors recover funds from securities class action settlements, offering resources for timely claims submission and legal evaluations [5]

Core Viewpoint - A securities class-action lawsuit has been filed against Centene Corporation, alleging that the company misrepresented its business outlook, particularly regarding health insurance marketplace enrollment, leading to a significant stock price decline [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, seeks to represent investors who purchased Centene securities between December 12, 2024, and June 30, 2025 [2]. - The complaint claims that Centene projected a strong outlook based on robust enrollment and favorable morbidity rates, which contradicted the company's internal data [2][5]. - The lawsuit was prompted by Centene's abrupt withdrawal of its 2025 financial guidance on July 1, 2025, after an independent actuarial review indicated lower-than-expected market growth and inconsistent morbidity levels [3]. Group 2: Financial Impact - Following the revelation of the misleading information, Centene's stock price fell more than 40% in a single day [3]. - On July 25, 2025, Centene reported a second-quarter diluted loss per share of -$0.51, attributing this loss to reduced revenue estimates [4]. Group 3: Investigation and Legal Representation - Hagens Berman, a national plaintiffs' rights law firm, is investigating the claims against Centene to determine if the company misrepresented the health of its marketplace business [5]. - The firm emphasizes the alleged disconnect between Centene's public optimism and its internal data regarding its critical business segment [5].

Core Viewpoint - Rosen Law Firm is reminding purchasers of common units of XPLR Infrastructure, LP (formerly Nextera Energy Partners, LP) about a class action lawsuit and the upcoming lead plaintiff deadline on September 8, 2025 [1]. Group 1: Class Action Details - Investors who purchased XPLR common units between September 27, 2023, and January 27, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lead plaintiff must file a motion with the Court by September 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, XPLR made false and misleading statements regarding its operations as a yieldco, struggling to maintain operations and downplaying risks associated with financing arrangements [5]. - It is claimed that XPLR could not resolve its financing issues without risking significant unitholder dilution and planned to halt cash distributions to redirect funds to resolve these financings [5]. - The lawsuit asserts that the yieldco business model and distribution growth rate were unsustainable, leading to materially false and misleading public statements by the defendants [5].

Core Viewpoint - A securities class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors by making overly positive statements while concealing material adverse facts [2][6]. Allegations - The lawsuit claims that C3.ai and its executives misled investors regarding the company's performance and potential [2]. - The CEO's health issues significantly hindered the company's ability to close deals, and management failed to minimize the impact of these health issues on operations [6]. Triggering Event - On August 8, 2025, C3.ai announced disappointing preliminary Q1 FY2026 results and cut full-year revenue guidance, attributing weak sales to "reorganization with new leadership" and the CEO's health problems [6]. Stock Impact - Following the announcement on August 8, 2025, C3.ai's stock closed at $22.13 per share and fell to $16.47 per share by August 11, 2025, representing a drop of approximately 25.6% in a single trading day [6]. Next Steps for Investors - Investors who suffered losses can seek appointment as lead plaintiff prior to October 21, 2025, by contacting Wolf Haldenstein [2][6].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to significant financial misrepresentations and integration issues related to its acquisition of 3M's food safety business, which led to substantial losses for investors during the specified class period [1][6]. Financial Performance - On January 10, 2025, Neogen reported a GAAP net income that was significantly negative, primarily due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, resulting in a share price decline from $13.07 to $12.36, approximately 5% [3]. - On April 9, 2025, Neogen's quarterly revenue fell by 3.4% to $221 million, leading to another cut in FY25 guidance and a share price drop from $7.04 to $5.02, approximately 28% [4]. - On June 4, 2025, Neogen disclosed a material decline in EBITDA margin attributed to elevated inventory write-offs, causing the share price to decline from $6.00 to $4.96, approximately 17% [5]. Lawsuit Details - The lawsuit alleges that Neogen misrepresented the status of the integration with 3M and failed to disclose the negative impacts of integration issues, misleading investors into believing that the integration was progressing smoothly [6].